Altimmune: 'Positive Results in 12-week Phase 1 Obesity Trial'

 

• Mean weight loss of 10.3% achieved in subjects receiving 1.8 mg dose

• Pemvidutide was well-tolerated without the need for dose titration

• No discontinuations due to treatment-emergent adverse events

• NASH IND has cleared FDA review; 12-week NAFLD study to begin in the near future

• Altimmune to host a conference call today at 8:30 am EST

Conference Call Information
Altimmune management will host a conference call and webcast with a slide presentation beginning at 8:30 am E.T. Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company’s website at www.altimmune.com. The company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Date:		Tuesday, September 28
Time:		8:30 am Eastern Time
Domestic Dial-in:		(844) 615-6509
International Dial-in:		(918) 922-3148
Conference ID:		3792068
Webcast: https://finance.yahoo.com/news/altimmune-announces-positive-results-12-110100084.html		https://edge.media-server.com/mmc/p/ojyxaxpp